You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Meny

  • Webinar | People migrating to the UK on TLD

    Dovato (doltegravir/lamivudine | Abbreviated Prescribing Information

    Chapter 1 | What are the considerations?

    Chapter 2 | What are the considerations?

    POM A. Marketing Authorisation Number: EU/1/20/1481/003. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.

    Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.

  • DOVATO | CLOSE THE GAP HIGH BARRIER TO RESISTANCE

    Dovato (doltegravir/lamivudine) | Abbreviated Prescribing Information

    POM A. Marketing Authorisation Number: EU/1/20/1481/003. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.

    Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

    PM-IE-DLL-WCNT-240009 | Date of Preparation: October 2024

  • PASO DOBLE STUDY DR. ESTEBAN MARTINEZ

    Dovato (dolutegravir/lamivudine) | Abbreviated Prescribing Information

    POM A. Marketing Authorisation Number: EU/1/20/1481/003. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.

    Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

    PM-IE-DLL-WCNT-240008 | Date of Preparation: July 2025

  • A 7 Chapter Webinar: Dr Jan Borch on Long-Acting Injectables

    Vocabria▼ + Rekambys▼ Abbreviated Prescribing Information

    Overview of LAI studies in ARV therapy

    Chapter 1 of 7

    CVF rates in LAI studies

    Chapter 2 of 7

    Vocabria & Rekambys Patient Case Study 1

    Chapter 3 of 7

    Vocabria & Rekambys Patient Case Study 2

    Chapter 4 of 7

    Vocabria & Rekambys Patient Case Study 3

    Chapter 5 of 7

    Patients who may benefit from LAI

    Chapter 6 of 7

    Safety Information for Vocabria and Rekambys

    Chapter 7 of 7

    POM A. Marketing Authorisation Number: EU/1/20/1481/003. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.

    Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

    ▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

    PM-IE-CBR-WCNT-240003 | Date of Preparation: June 2024

  • A Three Chapter Webinar with Professor Guaraldi on The Art of Individualised Care: Making HIV a Smaller Part of Our Patients’ Lives

    Dovato Abbreviated Prescribing Information

    Frailty in HIV Patients

    Chapter 1 of 3

    Ageing Healthy with HIV

    Chapter 2 of 3

    Benefits of Patient Reported Outcomes

    Chapter 3 of 3

    POM A. Marketing Authorisation Number: EU/1/19/1370/001-004. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.

    Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

    PM-IE-DLL-WCNT-240001 | Date of Preparation: June 2024

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor.

GSK group of companies. All rights reserved.

Date of preparation: October 2025 | PM-IE-HVX-WCNT-240001